Institution
University of Alabama
Education•Tuscaloosa, Alabama, United States•
About: University of Alabama is a education organization based out in Tuscaloosa, Alabama, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 27323 authors who have published 48609 publications receiving 1565337 citations. The organization is also known as: Alabama & Bama.
Topics: Population, Poison control, Galaxy, Health care, Large Hadron Collider
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The role of PEN1 and of its closest homologue, SYP122, identified as a syntaxin whose expression is responsive to infection are examined, which concludes thatSYP122 may have a general function in secretion, including a role in cell wall deposition.
Abstract: Attack by the host powdery mildew Erysiphe cichoracearum usually results in successful penetration and rapid proliferation of the fungus on Arabidopsis. By contrast, the nonhost barley powdery mild...
368 citations
••
TL;DR: The endothelin receptor antagonist tezosentan did not improve symptoms or clinical outcomes in patients with acute heart failure and was not associated with worse outcomes.
Abstract: ContextPlasma concentrations of the vasoconstrictor peptide endothelin-1 are increased in patients with heart failure, and higher concentrations are associated with worse outcomes. Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemodynamic actions in heart failure.ObjectiveTo determine if tezosentan improves outcomes in patients with acute heart failure.Design, Setting, and ParticipantsThe Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies, 2 independent, identical, and concurrent randomized, double-blind, placebo-controlled, parallel-group trials conducted from April 2003 through January 2005 at sites in Australia, Europe, Israel, and North America. Patients admitted within the previous 24 hours with persisting dyspnea and a respiratory rate of 24/min or greater were eligible provided they fulfilled 2 of 4 criteria: (1) elevated plasma concentrations of B-type or N-terminal pro–B-type natriuretic peptide, (2) clinical pulmonary edema, (3) radiologic pulmonary congestion or edema, or (4) left ventricular systolic dysfunction.InterventionInfusion of tezosentan (5 mg/h for 30 minutes, followed by 1 mg/h for 24 to 72 hours [n = 730]) or placebo (n = 718).Main Outcome MeasuresThe coprimary end points were change in dyspnea (measured at 3, 6, and 24 hours using a visual analog scale from 0-100) over 24 hours (as area under the curve) in the individual trials and incidence of death or worsening heart failure at 7 days in both trials combined.ResultsOf the 1435 patients who received treatment as assigned, 855 (60%) were men; mean age was 70 years. Mean left ventricular ejection fraction (measured in 779 patients [54%]) was 29% (SD, 11%). Baseline dyspnea scores were similar in the 2 treatment groups. Tezosentan did not improve dyspnea more than placebo in either trial, with a mean treatment difference of −12 (95% confidence interval [CI], −105 to 81) mm · h (P = .80) in the first trial and −25 (95% CI, −119 to 69) mm · h (P = .60) in the second. The incidence of death or worsening heart failure at 7 days in the combined trials was 26% in each treatment group (odds ratio, 0.99; 95% confidence interval, 0.82-1.21; P = .95).ConclusionThe endothelin receptor antagonist tezosentan did not improve symptoms or clinical outcomes in patients with acute heart failure.Trial Registrationclinicaltrials.gov Identifiers: NCT00525707 (VERITAS-1) and NCT00524433 (VERITAS-2).
368 citations
••
TL;DR: Kudzu was found to be an effective adsorbent for basic dye colour removal; though its capacity for colour removal was not as high as an activated carbon, the potential appeared to exist to use it as an alternative to activated carbon where carbon cost was prohibitive.
368 citations
••
TL;DR: Ionic liquids (ILs) are composed of organic cations and either organic or inorganic anions that remain liquid over a wide temperature range, including room temperature.
366 citations
••
TL;DR: The Cryptococcus has become a major cause of meningitis in patients infected with the human immunodeficiency virus (HIV), and the expression of cryptococcal infection in this population of patients is quite unique.
Abstract: The Cryptococcus has become a major cause of meningitis in patients infected with the human immunodeficiency virus (HIV), and the expression of cryptococcal infection in this population of patients is quite unique. Often the infection is devoid of inflammatory response and is associated with very high antigen and fungal titers. Response to amphotericin therapy is erratic, and relapse is common. We have asked Dr. William E. Dismukes, principal investigator of the NIAID Mycoses Study Group, to discuss the following clinical questions: When and how does cryptococcal infection in HIV-infected patients present? How does it differ in HIV-infected and non-HIV-infected individuals? How is the diagnosis established? What is the sensitivity of the CSF cryptococcal antigen test? Is the serum antigen test of any value? What is the best way to treat patients--the recommended drugs, dosages, and duration of therapy? Is maintenance therapy necessary, and finally, what drugs are available for it? [Please note that an AIDS training program is now available for members of the Infectious Diseases Society of America and that details of this program appear in the Notices section of this Journal issue (pages 859-60).]
365 citations
Authors
Showing all 27508 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jasvinder A. Singh | 176 | 2382 | 223370 |
Hongfang Liu | 166 | 2356 | 156290 |
Ian J. Deary | 166 | 1795 | 114161 |
Yongsun Kim | 156 | 2588 | 145619 |
Dong-Chul Son | 138 | 1370 | 98686 |
Simon C. Watkins | 135 | 950 | 68358 |
Kenichi Hatakeyama | 134 | 1731 | 102438 |
Conor Henderson | 133 | 1387 | 88725 |
Peter R Hobson | 133 | 1590 | 94257 |
Tulika Bose | 132 | 1285 | 88895 |
Helen F Heath | 132 | 1185 | 89466 |
James Rohlf | 131 | 1215 | 89436 |
Panos A Razis | 130 | 1287 | 90704 |
David B. Allison | 129 | 836 | 69697 |
Eduardo Marbán | 129 | 579 | 49586 |